TREATMENT OF CELLULAR HYPERPROLIFERATION BY INHIBITION OF INTERLEUKIN-1

Abstract: Methods of treating conditions characterized by cellular hyperproliferation using Interleukin-1 inhibitory compounds and compounds useful in the described methods are provided.

Description: DESCRIPTION Treatment of Cellular Hyper-Proliferation bv Inhibition of Interleukin-1 Cross-Reference to Related Applications The present application is a continuation in part of United States Serial No. 07/707,897 filed May 31, 1991, the disclosure of which is incorporated herein by reference. Background of the Invention The present invention is directed to methods of treatment of cellular hyperproliteration. These methods are useful in the treatment of various pathologic con- ditions characterized by over-proliferation of cells, especially epithelial cells and, more particularly, keratinocytes. Conditions characterized by hyperproliferation of cells, particularly keratinocytes, have proved difficult to treat. Conventional therapies for some of these conditions such as psoriasis have been unsatisfactory. Thus, there exists a need for therapies which can treat these conditions by decreasing or preventing over- proliferation of cells. Cytokine levels in certain conditions characterized by cellular hyperproliferation have been studied. In particular, there have been attempts to compare levels of Interleukin-lα and Interleukin-13 in normal and in psori- atic skin. Interleukin-1 activity in psoriatic skin has been reported to be reduced in relation to normal skin. However, in psoriatic skin higher levels of a high mole-, cular weight Interleukin-1S in comparison to Interleukin- 1/3 levels in normal skin form have been reported. (See, Cooper et al., J. Invest. Dermatol. .95.(5) :245 to 265 (1990) ) . Summary of the Invention The present invention provides methods of preventing or decreasing hyperproliferation of cells, particularly epithelial cells, by inhibiting or decreasing inhibition of Interleukin-1 ("IL-l") activity or intracellular Inter- leukin-1 receptor antagonist activity. Thus, the present invention is directed to such methods which comprise con¬ tacting the cells with a hyperproliferation inhibiting amount of an Interleukin-1 inhibitory compound. Inter- leukin-1 inhibitory compounds include compounds which decrease Interleukin-1 or intracellular Interleukin-1 receptor antagonist activity. According to one aspect, Interleukin-1 activity is inhibited by inhibiting or down- regulating its synthesis. According to another aspect, Interleukin-1 activity is inhibited by inhibiting conver¬ sion of a precursor form into an active form. This inhi¬ bition of conversion into an active form may be accom¬ plished by one of several means, including, but not lim¬ ited to, preventing or decreasing expression of a convert- ing enzyme which converts a precursor form into an active form or by inhibiting the converting enzyme per se. Suit¬ able Interleukin-1 inhibitory compounds include Oligomerε (such as antisense Oligomers, Third Strand Oligomers or Triplex Oligomer Pairs) which regulate expression of an Interleukin-1, an Interleukin-1 modulating factor, or an Interleukin-1 converting enzyme. Interleukin-1 modulating factors include compounds which modulate Interleukin-1 activity and include, for example, compounds such as intracellular Interleukin-1 receptor antagonist. Other Interleukin-1 inhibitory compounds may be selected from a variety of classes of compounds which decrease activity levels of Interleukin-1 or intracellular Interleukin-1 receptor antagonist in the targeted (i.e., hyperprolifer- ating) cells. According to a preferred aspect, the present inven¬ tion is directed to methods of treating pathologic condi¬ tions characterized by hyperproliferation of skin or epithelial cells by contacting skin or epithelial cells with a proliferation-inhibiting amount of Oligomer(s) . The Oligomer may be an antisense Oligomer, a Third Strand Oligomer or a Triplex Oligomer. Such an antisense Oligo- mer has a sequence complementary to a sequence of RNA transcribed from a target gene present in the cells. A Triple Strand Oligomer has a sequence complementary to a selected double stranded nucleic acid sequence of a target gene present in the cells. A Triplex Oligomer Pair is complementary to a single stranded nucleic acid sequence of a target gene or its transcription product. The target gene is selected from those genes which encode a cytokine which mediates cellular proliferation or a modulating fac¬ tor (such as a receptor antagonist) thereof or a convert- ing enzyme therefor. According to an alternate preferred aspect, the present invention is directed to methods of decreasing or preventing hyperproliferation of skin or epithelial cells by contacting the cells with a hyperproliferation- inhibiting amount of an Oligomer which comprises an antisense Oligomer, a Triple Strand Oligomer or a Triplex Oligomer Pair. The Oligomer has a sequence complementary to a nucleic acid sequence from a target gene present in the cells or transcription product. The target gene is selected from those genes encoding cytokines which mediate cellular proliferation, or a modulating factor such as a receptor antagonist for such a cytokine, or a converting enzyme, or an enzyme involved in translational or post- translational modification of the cytokine that is criti- cal for its function. Preferred target genes include those which encode Interleukin-18 ("IL-13 M ) , Interleukin-lα ("IL-lα"), intracellular Interleukin-1 receptor antagonist ("icIL- lra" or "intracellular IL-lra"), or an Interleukin-1 converting enzyme. Definitions As used herein, the following terms have the follow¬ ing meanings unless expressly stated to the contrary. The term "purine" or "purine base" includes not only the naturally occurring adenine and guanine bases, but also modifications of those bases such as bases substi¬ tuted at the 8- position, or to the guanine analogs modi¬ fied at the 6-position or the analog of adenine, 2-amino purine. The term "nucleoside" includes a nucleosidyl unit and is used interchangeably therewith, and refers to a subunit of a nucleic acid which comprises a 5 carbon sugar and a nitrogen- containing base. The term includes not only units having A, G, C, T and U as their bases, but also analogs and modified forms of the bases (such as 8-sub- stituted purines) . In RNA, the 5 carbon sugar is ribose; in DNA, it is a 2' -deoxyribose. The term also includes analogs of such subunits, including modified sugars such as 2'-0-alkyl ribose. I 0 I The term "phosphonate" refers to the group 0=P-R wherein R is an alkyl or aryl group. Suitable alkyl or aryl groups include those which do not sterically hinder the phosphonate linkage or interact with each other. The phosphonate group may exist in either an "R" or an "S" configuration. Phosphonate groups may be used as inter- nucleosidyl phosphorus group linkages (or links) to con¬ nect nucleosidyl units. O The term "phosphodiester" refers to the group 0=P-0 I o I wherein phosphodiester groups may be used as internucleo- sidyl phosphorus group linkages (or links) to connect nucleosidyl units. A "non-nucleoside monomeric unit" refers to a mono- meric unit wherein the base, the sugar and/or the phos¬ phorus backbone has been replaced by other chemical moieties. A "nucleoside/non-nucleoside polymer" refers to a polymer comprised of nucleoside and non-nucleoside mono- meric units. The term "oligonucleoside" or "Oligomer" refers to a chain of nucleosides which are linked by internucleoside linkages which is generally from about 6 to about 100 nucleosides in length, but which may be greater than about 100 nucleosides in length. They are usually synthesized form nucleoside monomers, but may also be obtained by enzymatic means. Thus, the term "Oligomer" refers to a chain of oligonucleosides which have internucleosidyl linkages linking the nucleoside monomers and, thus, includes oligonucleotides, nonionic oligonucleoside alkyl- and aryl-phosphonate analogs, alkyl- and aryl-phosphono- thioates, phosphorothioate or phosphorodithioate analogs of oligonucleotides, phosphoramidate analogs of oligo¬ nucleotides, neutral phosphate ester oligonucleoside analogs, such as phosphotriesters and other oligonucleo¬ side analogs and modified oligonucleosides, and also includes nucleoside/non-nucleoside polymers. The term also includes nucleoside/nucleotide polymers wherein one or more of the phosphorus group linkages between monomeric units has been replaced by a non-phosphorous linkage such as a formacetal linkage, a sulfamate linkage, or a carba- mate linkage. It also includes nucleoside/non-nucleoside polymers wherein both the sugar and the phosphorous moiety have been replaced or modified such as morpholino base analogs, or polyamide base analogs. It also includes nucleoside/non-nucleoside polymers wherein the base, the sugar, and the phosphate backbone of the non-nucleoside are either replaced by a non-nucleoside moiety or wherein a non-nucleoside moiety is inserted into the nucleoside/ non-nucleoside polymer. Optionally, said non-nucleoside moiety may serve to link other small molecules which may interact with target sequences or alter uptake into target cells. The term "alkyl- or aryl-phosphonate Oligomer" refers to Oligomers having at least one alkyl- or aryl-phospho¬ nate internucleosidyl linkage. Suitable alkyl- or aryl- phosphonate groups include alkyl- or aryl- groups which do not sterically hinder the phosphonate linkage or interact with each other. Preferred alkyl groups include lower alkyl groups having from about 1 to about 6 carbon atoms. Suitable aryl groups have at least one ring having a con- jugated pi electron system and include carbocyclic aryl and heterocyclic aryl groups, which may be optionally substituted and preferably having up to about 10 carbon atoms. The term "methylphosphonate Oligomer" (or "MP- Oligomer") refers to Oligomers having at least one methylphosphonate internucleosidyl linkage. The term "neutral Oligomer" refers to Oligomers which have nonionic internucleosidyl linkages between nucleoside monomers (i.e., linkages having no net positive or nega- tive ionic charge) and include, for example, Oligomers having internucleosidyl linkages such as alkyl- or aryl- phosphonate linkages, alkyl- or aryl-phosphonothioates, neutral phosphate ester linkages such as phosphotriester linkages, especially neutral ethyltriester linkages; and non-phosphorus-containing internucleosidyl linkages, ■ such as sulfamate, morpholino, formacetal, and carbamate link¬ ages. Optionally, a neutral Oligomer may comprise a conjugate between an oligonucleoside or nucleoside/non- nucleoside polymer and a second molecule which comprises a conjugation partner. Such conjugation partners may comprise intercalators, alkylating agents, binding sub¬ stances for cell surface receptors, lipophilic agents, nucleic acid modifying groups including photo-cross- linking agents such as psoralen and groups capable of cleaving a targeted portion of a nucleic acid, and the like. Such conjugation partners may further enhance the uptake of the Oligomer, modify the interaction of the Oligomer with the target sequence, or alter the pharmaco- kinetic distribution of the Oligomer. The essential requirement is that the oligonucleoside or nucleoside/non- nucleoside polymer that the Oligomer conjugate comprises be neutral. The term "neutral alkyl- or aryl- phosphonate Oligo¬ mer" refers to neutral Oligomers having neutral inter¬ nucleosidyl linkages which comprise at least one alkyl- or aryl- phosphonate linkage. The term "neutral methylphosphonate Oligomer" refers to neutral Oligomers having internucleosidyl linkages which comprise at least one methylphosphonate linkage. The term "tandem oligonucleotide" or "tandem Oligo¬ mer" refers to an oligonucleotide or Oligomer which is complementary to a sequence located either on the 5'- or 3' - side of a target nucleic acid sequence and which is co-hybridized with a second Oligomer which is complemen¬ tary to the target sequence. Tandem Oligomers may improve hybridization of these Oligomers to the target by helping to make the target sequence more accessible to such Oligo¬ mers, such as by decreasing the secondary structure of the target nucleic acid sequence. In addition, one member of a pair of tandem Oligomers may improve the hybrid stabil¬ ity of the second tandem Oligomer to the target nucleic acid sequence by promoting a helical structure at either the 5'- or 3'-end of said second Oligomer and vice-versa. The term "short chain aliphatic alcohol" refers to an alcohol having from about 2 to about 20 carbon atoms in which the aliphatic (alkyl) chain may be either straight chained or branch chained and includes primary, secondary and tertiary alcohols, glycols and polyols. The term "flux enhancer" refers to a substance which is used to increase transdermal flux of a compound. A flux enhancer is typically applied to skin or mucous mem¬ brane in combination with the compound to increase trans- dermal flux of the compound. Enhancers are believed to function by disrupting the skin or mucous membrane barrier or by changing the partitioning behavior of the drug in the skin or mucous membrane. The term "Triplex Oligomer Pair" refers to first and second Oligomers which are complementary to and which are capable of hydrogen bonding to a segment of a single stranded target nucleic acid, such as RNA or DNA, and, thus, together with the single stranded target nucleic acid are capable of forming a triple helix structure therewith. The term "Third Strand Oligomer" refers to Oligomers which are capable of hybridizing to a segment of a double stranded nucleic acid, such as a DNA duplex, an RNA duplex or a DNA-RNA duplex, and forming a triple helix structure therewith. The term "complementary, " when referring to a Triplex Oligomer Pair (or first and second Oligomers) or to a Third Strand Oligomer, refers to Oligomers having base sequences which hydrogen bond (and base pair or hybridize) with the base sequence of the nucleic acid to form a triple helix structure. Detailed Description of the Invention According to the present invention, conditions char¬ acterized by hyperproliferation of cells, especially epi- thelial cells, are treated using a hyperproliferation inhibiting amount of an Interleukin-1 inhibitory compound. Interleukin-1 inhibitory compounds include compounds which decrease Interleukin-1 or intracellular Interleukin-1 receptor antagonist activity. Suitable Interleukin-1 inhibitory compounds include compounds which inhibit or decrease expression of a Interleukin-1, an Interleukin-1 modulating factor, such as intracellular Interleukin-1 receptor antagonist, or an enzyme which converts an IL-l precursor to an active form ("converting enzyme") and, thus, includes peptides, competitive or non-competitive inhibitors for converting enzymes, small molecule inhibi¬ tors, antibodies, Oligomers which bind to a protein's active site to modulate its function, or Oligomers such as antisense Oligomers, Third Strand Oligomers and Triplex Oligomer Pairs. Suitable nucleoside sequences for these Oligomers may be determined from the sequences of target genes. Preferred sequences of the target region are described herein below. Other suitable Interleukin-1 inhibitory compounds include compounds which inhibit a converting enzyme and, thus, prevent conversion of an IL-l precursor into an active form. Other Interleukin-1 inhi¬ bitory compounds include compounds which decrease intra¬ cellular Interleukin-1 receptor antagonist activity. A. Preferred Oligomers The Oligomer selected may be any of a number of types, including those having a charged or uncharged backbone. Preferred Oligomers include alkyl- and aryl-phos¬ phonate Oligomers, especially preferred are methylphos¬ phonate Oligomers. Other preferred Oligomers include phosphorothioate Oligomers, morpholino analogs, formacetal analogs and peptide nucleic acid ("PNA") analogs. Also preferred are Oligomers having at least about 8 nucleo¬ sidyl units, more preferably from about 8 to about 40 nucleosidyl units. Also preferred are Oligomers which are nucleoside/non-nucleoside polymers. Suitable Oligomers also include chimeric oligonucleotides which are composite RNA, DNA analogues (Inoue et al., FEBS Lett. 2115.:327 (1987)). Oligomers having a neutral backbone, for exam¬ ple, methylphosphonate Oligomers with cleaving or cross- linking moieties attached, may prove advantageous in certain circumstances; such Oligomers may have a longer half-life in vivo since the neutral structure reduces the rate of nuclease digestion while the cleaving or cross- linking moiety may promote inactivation of target poly- nucleotide sequences. According to one aspect of the present invention, these antisense Oligomers have a sequence which is com¬ plementary to a portion of the RNA transcribed from the selected target gene. Although the exact molecular mech¬ anism of inhibition has not been conclusively determined, it has been suggested to result from formation of duplexes between the antisense Oligomer and the RNA transcribed from the target gene. The duplexes so formed may inhibit translation, processing or transport of an mRNA sequence or may lead to digestion by the enzyme RNaseH. According to an alternate aspect of the present invention, down regulation of cellular proliferation may be accomplished by triple helix formation using a Third Strand Oligomer or a Triplex Oligomer Pair having sequences selected such that the Oligomer(s) are comple- mentary to and form a triple helix complex with a target sequence of double stranded or single stranded nucleic acid and thereby interfere with or prevent expression of the targeted nucleic acid sequence. Further descriptions of the use of Oligomers (including Third Strand Oligomers and Triplex Oligomer Pairs) to prevent or interfere with the expression of a target sequence of double or single stranded nucleic acid by formation of triple helix com¬ plexes is described in the copending U.S Patent Applica¬ tion Serial Nos. 07/388,027, 07/751,813 and 07/772,081, the disclosures of which are incorporated herein by reference. As a general matter, the Oligomer employed will have a sequence that is complementary to the sequence of the target nucleic acid. However, absolute complementarity may not be required; in general, any Oligomer having sufficient complementarity to form a stable duplex (or triple helix complex as the case may be) with the target nucleic acid is considered to be suitable. Since stable duplex formation depends on the sequence and length of the hybridizing Oligomer and the degree of complementarity between the antisense Oligomer and the target sequence, the system can tolerate less fidelity (complementarity) when longer Oligomers are used. This is also true with Oligomers which form triple helix complexes. However, Oligomers of about 8 to about 40 nucleosidyl units in length which have sufficient complementarity to form a duplex or triple helix structure having a melting tem¬ perature of greater than about 40°C under physiological conditions are particularly suitable for use according to the methods of the present invention. The concentration of Oligomer used may vary, depend- ing upon a number of factors, including the type of hyper- proliferative condition to be treated, the tissue to be treated (i.e., whether administered locally or systemic- ally) , the type and the specificity of the particular antisense Oligomer selected. The studies described herein have observed significant inhibition in the test systems used at concentrations in the 50 μM range; however, under other conditions, higher or lower concentrations of Oligo¬ mer may be preferred. For indications where Oligomers are to be adminis- tered transdermally, preferred are neutral Oligomers. For indications where Oligomers are to be adminis¬ tered parenterally, such as by injection, either neutral Oligomers or Oligomers having an ionically charged back¬ bone (i.e.. having charged internucleosidyl linkages) may be used. According to one preferred aspect, these Oligomers may comprise a conjugate between a polynucleoside or nucleoside/non-nucleoside polymer and a conjugation part¬ ner. Suitable conjugation partners include intercalating agents such as acridine, alkylating agents, binding sub¬ stances for cell surface receptors, lipophilic agents, photo-crosslinking agents such as psoralen, other cross- linking agents, pro-chelates, or nucleic acid modifying agents, including groups capable of cleaving a targeted portion of a nucleic acid such as hydrolytic or nucleo- lytic agents like o-phenanthroline copper or EDTA-iron, all of which may be incorporated in the Oligomers. Conjugation partners may also be introduced into the Oligomer by the incorporation of modified nucleosides or nucleoside analogs through the use of enzymes or by chem¬ ical modification of the Oligomer, for example, by the use of non-nucleotide linker groups. When used to prevent function or expression of a single or double stranded nucleic acid sequence, these Oligomers may be advantageously derivatized or modified to incorporate a nucleic acid modifying group which may be caused to react with said nucleic acid and irreversibly modify its structure, thereby rendering it non-functional. Commonly assigned USSN 565,299, the disclosure of which is incorporated herein by reference, discloses psoralen-derivatized Oligomers. As discussed above, a wide variety of nucleic acid modifying groups may be used as conjugation partners to derivatize these Oligomers. Nucleic acid modifying groups include groups which, after the derivatized Oligomer forms a complex which a single stranded or double stranded nucleic acid segment, may be caused to cross-link, alkyl- ate, cleave, degrade, or otherwise inactivate or destroy the nucleic acid segment or a target sequence portion thereof, and thereby irreversibly inhibit the function and/or expression of that nucleic acid segment. The location of the nucleic acid modifying groups in the Oligomer may be varied and may depend on the parti¬ cular nucleic acid modifying group employed and the tar¬ geted nucleic acid segment. Accordingly, the nucleic acid modifying group may be positioned at the end of the Oligo- mer or intermediate between the ends. A plurality of nucleic acid modifying groups may be included. In one preferred aspect, the nucleic acid modifying group is photoreactable (e.g., activated by a particular wavelength, or range of wavelengths of light) , so as to cause reaction and, thus, cross-linking between the Oligo- mer and the nucleic acid target. Exemplary of nucleic acid modifying groups which may cause cross-linking are the psoralens, such as an amino- methyltrimethyl psoralen group (AMT) . The AMT is advan¬ tageously photoreactable, and thus must be activated by exposure to particular wavelength light before cross- linking is effectuated. Other cross-linking groups which may or may not be photoreactable may be used to derivatize these Oligomers. Alternatively, the nucleic acid modifying groups may comprise an alkylating agent group which is covalently bonded to the nucleic acid segment to render it inactive. Suitable alkylating agent groups are known in the chemical arts and include groups derived from alkyl halides, halo- acetamides and the like. Polynucleotide modifying groups which may be caused to cleave the polynucleotide segment include moieties which generate radicals, as well as moieties, which promote hydrolysis through nucleophilic attack. Transition metal chelating complexes, such as ethylenediaminetetraacetate (EDTA) or a neutral derivative thereof, can be used to generate radicals. Other groups which may be used to effect radical mediated cleavage include phenanthroline, porphyrin and the like. When EDTA is used, iron may be advantageously tethered to the Oligo¬ mer to help generate the cleaving radicals. Although iron-EDTA is a preferred polynucleotide cleaving group, other nitrogen containing materials, such as azo compounds or nitrenes or other transition metal chelating complexes may be used. Yet other cleavage agents include nucleo¬ philic agents and hydrolytic agents that promote the addi- tion of water at the phosphorus internucleotide linkages. Such agents include amines, substituted guanidinium groups, imidazole groups and the like. 1. Preferred Neutral Oliσomer Formulations Preferred neutral Oligomers include neutral alkyl- and aryl- phosphonate Oligomers and neutral Oligomers comprising morpholino or phosphoramidate linkages. Especially preferred are neutral methylphosphonate Oligomers. In view of their demonstrated ability to penetrate skin, including tape stripped skin, (which has had the stratum corneum removed and which has been reported as a model for mucous membrane) , particularly preferred are neutral methylphosphonate Oligomers having only methylphosphonate internucleosidyl linkages. Synthetic methods for preparing methylphosphonate Oligomers are described in Example 1 herein and also in Lee B.L., et al., Biochemistry 22:3197-3203 (1988), and Miller, P.S., et al., Biochemistry 25..5092-5097 (1986), the disclosures of which are incorporated herein by reference. According to another aspect of the present invention, preferred are Oligomers which may be neutral until they enter cells and once inside are converted to charged species through chemical or biological processes. Such charged oligonucleotides may contain other moieties that stabilize the oligonucleotides to nuclease degradation. Substituents such as 2'-O-methylribose groups, various base modification, and analogs of the phosphorous back¬ bone, such as phosphorothioates, can increase resistance to nucleases. Additionally, the presence of methylphos¬ phonate or other neutral internucleoside linkages in the Oligomer give exonuclease resistance. Preferred are neutral Oligomers having from about 6 to about 40 nucleosides, more preferably from about 12 to about 20 nucleosides. Although neutral Oligomers which comprise more than 20 nucleosides may be used, where com¬ plementarity to a longer sequence is desired, it may be advantageous to employ shorter neutral tandem Oligomers to maximize solubility and penetration through the skin or mucous membranes while competing for the development of a secondary structure of the target nucleic acid, such as a RNA. Alternatively, it may be advantageous to use more than one neutral Oligomer, each Oligomer complementary to a distinct target sequence which may be part of the same gene or a different gene. Where the neutral Oligomers comprise alkyl- or aryl- phosphonate Oligomers, it may be advantageous to incor¬ porate nucleoside monomeric units having modified ribosyl moieties. The use of nucleoside units having 2'-0-alkyl- and, in particular, 2' -O-methyl-ribosyl moieties in these neutral oiigomers may advantageously improve hybridization of the Oligomer to its complementary target sequence. Suitable formulations comprise about 0.0001% to about 2% by weight of neutral Oligomer. In one preferred aspect, there are provided neutral Oligc- ar formulations which comprise about 2% to about 100% wf a short chain aliphatic alcohol. Suitable alco¬ hols include ethanol, isopropyl alcohol, propylene glycol and glycerol. In certain studies, formulations of neutral Oligomers comprising ethanol have demonstrated advanta¬ geous transdermal flux. In an especially preferred aspect, these neutral Oligomer formulations may additionally comprise a flux enhancer. Suitable flux enhancers include those known to those skilled in the art and include decylmethylsulfoxide, dimethylsulfoxide as well as cyclic ketones, lactones, anhydrides and esters such as those described in PCT Application No. PCT/US86/02583 (Publication Number W087/ 03473) . Some of these flux enhancers also increase retention of the Oligomer and, thus, act to increase the concentration of Oligomer within the skin itself. Thus, for Oligomer formulations for direct (local) treatment, such as topical application to skin, it is preferred to use a flux enhancer which not only maximizes transdermal flux, but increases Oligomer retention in the skin. Certain cyclic ketone and lactone enhancers have been reported to increase local retention as well and, thus, comprise a preferred class of enhancers for topical administration of Oligomer formulations. In Oligomer formulations for systemic treatment, it is preferable to use a flux enhancer which maximizes flux with a minimal increase of local retention of Oligomer. 2. Preferred Tarσet Genes and Target Sequences According to a preferred aspect, the present inven¬ tion is directed to methods of preventing or decreasing cellular proliferation using Oligomers which interfere with expression of cytokines which influence cellular proliferation, with conversion of such cytokines from a precursor to an active form, or with the expression of an intracellular receptor antagonist thereof. Suitable Oligomers include antisense Oligomers, Third Strand Oligomers and Triplex Oligomer Pairs. According to one aspect of the present invention, there are provided methods of decreasing cellular hyper¬ proliferation by preventing or interfering with expression of Interleukin-1/3 (IL-l/3) , Interleukin-lα (IL-lα) or intracellular splice variant of Interleukin-1 receptor antagonist ("intracellular Interleukin-1 receptor antago¬ nist" or icIL-lra) or a IL-l converting enzyme, such as an IL-l/3 converting enzyme by administration of an Oligomer which is complementary to a target sequence on the DNA or a mRNA transcribed therefrom which codes for IL-l/3, for IL-lα, for icIL-lra, or for an IL-l/3 converting enzyme. Thus, the present invention is directed to methods of decreasing hyperproliferation of keratinocytes or other epithelial cells by exposing the cells to a proliferation inhibiting amount of an Oligomer, either an antisense Oligomer, a Third Stand Oligomer or a Triplex Oligomer Pair. The antisense Oligomer is complementary to a sequence of RNA transcribed from a target gene. The Third Strand Oligomer has a base sequence selected so that it is capable of hydrogen bonding with a sequence of a double stranded nucleic acid and forming a triple helix complex therewith. The first and second Oligomers of the Triplex Oligomer Pair have sequences selected such that they are complementary to and capable of hydrogen bonding with a targeted single-stranded nucleic acid sequence and together with the single stranded nucleic acid form a triple helix complex. The target gene is selected from the group consisting of those genes encoding a cytokine which mediates cellular proliferation or a receptor antagonist or converting enzyme therefor. Cytokines which comprise suitable targets include IL- lα and IL-l/3. Since IL-l / 3 is synthesized as a precursor of 31 K Daltons and for extracellular activity needs to be converted into an active form which is reported to be 17.5 K Daltons, a gene encoding an IL-l/3 converting enzyme is an alternate preferred target gene. Other alternate pre¬ ferred target genes include those encoding other enzymes also involved in translational or post-translational modi¬ fication of IL-l family molecules that are critical for function of IL-lα, IL-l3 or IL-lra (for example, myristy- lation) . Certain regions in the transcription product of the selected gene are preferred targets for the Oligomer. Oligomers of appropriate length, preferably from about 8 to 40 nucleotides, more preferably from about 12 to about 20 nucleosides, are selected so as to be adjacent to or cover these sites when hybridized to the target, in part or in whole. Such sites include, in the pre-mRNA, splice acceptor, splice donor, and splice branch points, and polyA addition region. The preferred sites in mRNA include the initiation codon, or the 5' end of the mRNA (cap site) . The sequence of the Oligomers would be the reverse complement of the sequence of the targeted region. As examples, in the case of IL-l/3 these sites would include the following, with reference to the nucleotide positions of the human IL-l/3 gene (GenBank accession number M15840) : Splice acceptor, nucleotide positions:445/446 ; 908/909; donor junctions 970/971; 1535/1536 1587/1588 3575/3576 3777/3778 4322/4323 4487/4488 5722/5723 5853/5854 6569/6570 Poly A addition nucleotide positions 7367-7372 signal Initiation nucleotide positions 924-926 codon mRNA cap site . nucleotide positions 374. As examples of preferred sites in the case of IL-lα, these sites and nucleotide positions with reference to the sequence numbers of human IL-lα gene (GenBank accession number X03833) include the following: Splice acceptor, nucleotide positions 1488/1489, donor junctions 2152/2153 2207/2208 3165/3166 3214/3215, 4102/4103 4325/4326 6261/6262, 6432/6433 7814/7815, 7939/7940, 10289/10290. Poly A addition nucleotide positions 11618-11623 signal Initiation codon nucleotide positions 2161-2163 mRNA cap site nucleotide positions 1438 The following site is an example of a preferred site of icIL-lra, the site and nucleotide positions given are in reference to the nucleotide positions of intracellular splice-variant of the human IL-lra gene (GenBank accession number M55646) : Initiation codon nucleotide positions 123-125 Additional preferred target sites would comprise a mRNA cap site or splice junctions of the IL-lra gene. As examples of the preferred sites in IL-l/3 convert¬ ing enzyme are the following, sites and nucleotide posi¬ tions of the human IL-l / 3 converting enzyme given in refer¬ ence to that gene (GenBank accession number M87507) : Initiation codon nucleotide positions 18-20 Poly A signal nucleotide positions 1316-1321 or 1335-1340 Additional preferred target sites would include an mRΝA cap or splice sites of the human IL-l/3 convertase. Thus, according to a preferred aspect of the present invention, Oligomers of the appropriate length, preferably from about 8 to 40 nucleosides and more preferably from about 12 to about 20 nucleosides, are selected so as to have sequences which hybridize to sites immediately adja- cent to these sites or hybridize with and cover these sites, in part or wholly, as defined by the nucleotide positions included above for IL-l/3, IL-lα, icIL-lra and IL-l/3 converting enzyme. When antisense Oligomers are used the sequence of the Oligomers is the reverse complement of the sequence of the targeted region. When Third Strand Oligomers are used, the Oligomers are selected to form sequence-specific hydrogen bonding interactions with the double stranded nucleic acid target. When Triplex Oligomer Pairs are used, the first and second Oligomers are selected so as to form sequence spe¬ cific hydrogen bonding interactions with a single stranded nucleic acid, and together form a triple helix structure. 3. Preferred Therapeutic Indications Preferred therapeutic indications include conditions which can be classed as (a) cutaneous, benign hyper-pro- liferative; (b) cutaneous, malignant hyper-proliferative; (c) epithelial, benign hyper-proliferative; (d) epithe¬ lial, malignant hyper-proliferative; and (e) non-epithe¬ lial, hyper-proliferative. Cutaneous conditions in which epidermal hyper¬ proliferation results in symptomatology include, but are not limited to, psoriasis, ichthyosis, pityriasis rubra pilaris ("PRP"), chronic dermatitis, psoriasifor derma¬ titis, atopic dermatitis, viral acanthoma (warts) , other benign growths, lichen simplex chronicus, and mycosis fungoides/Sezary syndrome. Malignant, cutaneous, hyper-proliferation of the epidermal keratinocytes include squamous cell carcinomas, basal cell carcinomas, actinic keratoses, keratoacanthomas and other epithelial neoplasms of the skin. Epithelial, non-malignant hyper-proliferative condi- tions include oral mucosal, vaginal, cervical, esophageal, pulmonary and gastrointestinal hyperplasias and dyspla- sias, laryngeal papillomas and bladder cystitis. Epithelial, malignant conditions of non-epidermal epithelial cells include squamous cell and other epi- thelial carcinomas of the head and neck, pulmonary tree, intestines, breast, bladder, cervix, uterus, and vagina. Non-epithelial hyper-proliferations may also be responsive. These include rheumatoid arthritis, poly- cystic renal disease, restenosis and fibrotic conditions of various organs. Non-epithelial cancers may also be targets. Also the methods of the present invention may be used in the treatment of conditions where preventing expression of IL-l family of proteins results in secondary inhibition of release of other cytokines, whereby the condition is ameliorated. Such conditions include, but are not limited to, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, uveitis or inflammation in psoriasis. a. Role of IL-lα, IL-lg, and IL-l Receptor Antagonist in Keratinocvte Growth A major fundamental issue is whether psoriasis is an immunological disorder or the result of unregulated kera¬ tinocvte growth. IL-l elicits activities in a wide var¬ iety of cell types that result in pathological effects that are seen in psoriasis. In addition, dysregulation of IL-l has been reported in psoriatic tissue and may have consequences to the disease state. (Cooper, K.D. et al., J. Invest. Dermatol.. 5.:245-265 (1990)) . Psoriatic tis¬ sue has been reported to have decreased levels of IL-lα (-1/10) and increased levels of IL-l/3 (~2x) over normal tissue (Cooper, K.D., et al., . Immunol. 144:4593-4603 (1990) ) . Also, an intracellular form of the IL-l receptor antagonist is expressed in normal epidermis and dominates functionally in psoriatic epidermis (Hammerberg, C, et al., "Interleukin-1 Receptor Antagonist in Normal and Psoriatic Epidermis," J Clin. Inves .. 1992 (in Press)), although the IL-l receptor antagonist is responsible for the IL-l inhibitory activity that dominates in psoriatic skin. (Kim, N-I, et al., "Psoriatic Skin Reveals the in vivo Presence of the Epidermal IL-l Inhibitor, " Arch. Dermatol. Res.. 1991 (in Press)). In the epidermis, all members of the IL-l family are present almost exclusively intracellularly and are not secreted, although they can be released. The cytokines are present as both precursor and product; however, IL-l/3 in normal or psoriatic tissue is processed into an inactive form as assayed by T-cell acti¬ vation. These results indicate a potential autocrine role of IL-l and/or IL-lra in keratinocyte growth control either intracellularly or extracellularly. Furthermore, IL-lα, IL-l3 and IL-lra intracellular levels increase as keratinocytes enter a growth cycle; conversely, an abnor¬ mal keratinocyte population present in psoriasis skin becomes blocked in S phase in association with a precipi¬ tous drop in IL-lα, IL-l3 and IL-lra levels (Hammerberg, C, Abstract, J.I.D., April, 1992). To assess the intracellular role of IL-lα, IL-l/3, and icIL-lra in the growth of keratinocytes, antisense Oligo¬ mers provide one of the few methods to examine the func¬ tional importance of the gene products. Antisense inhibi¬ tion of gene expression provides not only the specificity cf discrimination between genes but also between highly related genes. Two different keratinocyte cultures have been used in these studies. The normal keratinocyte cul¬ tures are derived from normal human skin by separating the epidermis and culturing the keratinocytes (Baadsgard, 0., et al., J. Invest. Dermatol. 95:275-282 (1990)) . Another culture is a keratinocyte cell line that retains the prop¬ erties of keratinocytes and can undergo terminal differen¬ tiation to form stratum corneum when transplanted into nude mice (Boukamp, P., et al., J. Cell. Biol. 106:761-771 (1988) ) . b. Inhibition of Keratinocyte Proliferation Inhibition of gene expression of IL-l/3, IL-lα and IL- lra was studied using Oligomers complementary to portions of the IL-l/3, IL-lα or icIL-lra mRNA. Two different kera¬ tinocyte cell lines were used in these studies. The nor- mal keratinocyte cultures were derived from normal human skin by separating the epidermis and culturing the kera¬ tinocyte cells. (See Baadsgard et al., supra. ) A second cell culture was a keratinocyte cell line that retained the properties of keratinocytes and which can undergo terminal differentiation to form stratum corneum when transplanted into nude mice (HaCaT cell line) . (See Barkamp et al, supra. ) Antisense Oligomers used in these studies were directed to the initiation codon of the individual gene target mRNA's or a splice junction and are shown in Table I along with additional sequences that have been used to assess sequence specificity. Table I Methylphosphonate Oligomers 01igomer# Target Sequence Site 1 [1252] human IL-l / 3 TTC-TGC-CAT-GGC-TGC initiation codon 2 [1421] human IL-l/3 CAC-CTG-TGT-AAA-AAG splice site 3 [1251] . human IL-lα GCC-ATC-TTG-ACT-TCT initiation codon 4 [1487] human IL-l GCC-ATG-GGG-AGG-GCC initiation codon receptor antagonist (intracel¬ lular splice- variant) Cl [1480] mismatch to TTG-TGC-CAT-GCC-TGC Oligomer #1 nucleotide [1251] mismatch C3 [1588] mismatch to GCG-ATC-TTC-ACT-TCT Oligomer #3 nucleotide [1588] mismatch C4 [1607] mismatch to GCG-ATC-GGG-ACG-GGC Oligomer #4 nucleotide [1487] mismatch From a review of the results reported in Examples 2 and 3 herein, expression of the IL-lα or IL-l / 3 cytokines or IL-lra in keratinocytes appears to be an essential function for their proliferation. The constitutive expression of these cytokines by keratinocytes and their intracellular localization suggests that the effects of the antisense Oligomers are on new continual synthesis. The capacity to limit or reduce the proliferation of keratinocytes in culture by the use of sequence specific antisense Oligomers indicates that these Oligomers will be useful to limit proliferation of keratinocytes in diseases such as psoriasis. In addition to IL-lα and IL-l/3, kera¬ tinocytes also produce a number of other cytokines that may lead to inflammatory cell infiltration of the dermis. Keratinocytes in psoriasis release a balance of cytokines that boost T-cell activation. (Chang, E.Y. , "T-Cell Acti¬ vation is Potentiated by Cytokines Released by Lesional Psoriatic, But Not Normal, Epidermis," Arch. Dermatol. , Submitted, 1992) . It might be expected that inhibiting keratinocyte proliferation may also have an effect upon the immune component of the disease, not only because the IL-l group is one of several synergizing cytokines respon¬ sible for boosting T-cell activation in psoriasis, but because changing the intracellular cytokine milieu by use of an antisense or Third Strand Oligomer to IL-l/3 or IL-lα one may also block release of other cytokines. To assist in understanding the present invention, the following examples are included which describe the results of a series of experiments. The following examples relat- ing to this invention should not, of course, be construed in specifically limiting the invention and such variations of the invention, now known or later developed, which would within the purview of one skilled in the art are considered to fall within the scope of the present inven- tion as hereinafter claimed. Examples Example 1 Preparation of Methylphosphonate Oligomers Neutral methylphosphonate Oligomers are synthesized using methylphosphonamidite monomer, according to the chemical methods described by P.S. Miller et al. (Nucleic Acids Res. .11:6225-6242 (1983)), A Jager and J. Engels (Tetrahedron Letters 25:1437-1440 (1984)) and M.A. Dorman et al. (Tetradhedron Letters £0:95-102 (1984)). Solid phase synthesis is performed on a Milligen Model 8800 DNA synthesizer. The programs used with the synthesizer are named MTHL_06 (main) and CPLAWll (coup¬ ling) and are obtained from the manufacturer. The reagent mixtures used are as follows: 1. Activator: 0.45 M tetrazole in acetonitrile. 2. Cap A: 40% acetic anhydride in acetonitrile. 3. Cap B: 0.625% dimethylaminopyridine in pyridine. 4. Deblock: 2.5% dichloroacetic acid in dichloromethane. 5. Oxidizer: 0.1 M I 2 in tetrahydrofuran/2,6- lutidine/water (74.82/25/0.18; v/v/v) . 6. Wash A: acetonitrile containing less than 30 ppm water. 7. Wash B: acetonitrile containing less than 30 ppm water. 8. Monomers: all monomers and diluted to 0.08 M in acetonitrile. 9. Support: The Oligomer is synthesized using a support acrylate beads derivatized with the appropriate nucleoside. The crude, protected methylphosphonate Oligomers are removed from the solid support by mixing with acetoni¬ trile/ethanol/concentrated ammonium hydroxide (45/45/10; v/v/v) for thirty minutes at room temperature. Next, the protecting groups are removed from the bases by addition of an equal volume of ethylenediamine (high quality) for 6 hours at room temperature. The resulting solution is diluted 10-fold with water and then neutralized with glacial acetic acid. The solution containing Oligomers is passed over a Sep-Pak w C18 cartridge (Millipore/Waters Bedford, MA) prepared according to the manufacturer's specification. The column is washed with water and the Oligomers are eluted with 50% acetonitrile in water. The methylphosphonate Oligomers are further purified by, for example, reverse-phase HPLC chromatography as follows: A Beckman System Gold HPLC is used with a What- man RAC II ODS-3 column (5 μ , 9 mm i.d. x 100 mm long) . Buffer A= 50 mM triethylammonium acetate (pH 7) ; Buffer B=50% acetonitrile in 50 mM triethylammonium acetate (pH 7) . The sample, dissolved in 10% acetonitrile/water, is loaded onto the column using an external pump. Next, the column is attached to the Beckman HPLC system and a gradient of 0 to 20% Buffer B over 5 minutes, followed by a gradient of 20 to 60% Buffer B over 40 minutes, is run at a flow rate of 3.0 ml/minute. Fractions are collected and those containing full length methylphosphonate Oligo¬ mer are pooled, evaporated under vacuum, and resuspended in 50% acetonitrile/water. Example 2 Inhibition of Proliferation of Normal Keratinocytes Using Antisense Oligomers Normal human keratinocytes were obtained by the procedure described by Baadsgaard et al. (J. Invest. Dermatol. 5:275-282 (1990)) and grown in keratinocyte growth medium (Clonetics, San Diego, CA) . Oligomer stocks were in 50% acetonitrile/H 2 0 and were diluted at least 100 fold to achieve a concentra¬ tion of lOOμM, in the culture medium, unless noted otherwise. The maximum amount of acetonitrile in the media was 0.5%. Cells were plated at 3 X 10 3 cells in a single well of a 96-well cell culture plate. The cells were main¬ tained at 37°C in a C0 2 incubator. After 4 days of growth, unless otherwise indicated, 3 H-dT (lμCi) was added and the label was incorporated for 6 hours. The acid-precipitable label was collected and the counts determined using a scintillation counter. For each treatment or control, six wells (replicates) were setup and run. Of the six replicates, the ones having highest and lowest number of counts were eliminated and the average value and error were calculated using the remaining four values. Treatment of freshly obtained normal keratinocytes cultured ex vivo with methylphosphonate (MP) antisense Oligomer to IL-lα or IL-l/3 was carried out for different lengths of time to evaluate the effect on growth when the cytokines are targeted. The results indicate tar¬ geting either IL-lα or IL-l/3 inhibits the proliferation (as measured by 3 H-thymidine incorporation into DNA) of normal keratinocytes in culture (Table II) and the extent of inhibition is dependent upon length of treat- ment and demonstrates a decrease in the rate of pro¬ liferation of the cells with antisense treatment. Oli¬ gomers targeted at either the IL-lS initiation codon region or a splice site both had similar inhibitory activity. Table II (1251-2 ] Relative to same day control. Table II (cont'd) MP Oligomer Time (days) 3 H-dT incor . Inhibition of growth 1,141 ± 111 57% 652 ± 88 70% To examine the sequence specificity of inhibition of proliferation, a methyl phosphonate ("MP") Oligomer was synthesized with the same base composition as an IL- l / S Oligomer (1252) but 2 nucleotides were exchanged in their position in the molecule, thus, the Oligomer would be expected to have low or no affinity for the targeted gene. The Oligomers were incubated with normal keratin¬ ocyte cultures for 4 days at 100 μM. Inhibition of nor¬ mal keratinocyte proliferation by the exact match Oligo- mer to IL-l/3 [Oligomer 1 (1252)] was 54% whereas the mismatch Oligomer [Oligomer Cl (1480)] did not inhibit proliferation and showed increased incorporation that was within the standard error of the assay (Table III) . The inhibition of normal keratinocyte proliferation that was seen for Oligomer 1 was sequence specific in that exchange of two nucleotides in the sequence of Oligomer Cl abolished any inhibitory effects of added Oligomer. Table III Specificity of IL1 β Inhibition of Normal Keratinocytes by MP-Oligomer (100 uM) MP Oligomer Time 3 H-dT incorp. Inhibition of growth Control 4 days 8,028 ± 1,169 (no Oligomer) 1 [IL-l/3 4 days 3,713 ± 930 54! (1252-2)] Cl [Mismatch 4 days 8,737 ± 3,113 (+10%) to IL-l / 3 (1480-1)] Example 3 Inhibition of Proliferation of a Keratinocyte Cell Line Using Antisense Oligomers An established human keratinocyte cell line HaCaT has also been used to provide a continuous source of cells. The cell line maintains some of the properties of keratinocytes most notably the capacity to terminally differentiate when transplanted onto immuno-compromised mice (Boukamp, P., et al., J. Cell. Biol. 106:761-771 (1988) ) . The HaCaT cell line was maintained in DMEM with 10% fetal calf serum. Oligomer stocks were kept and diluted as described in Example 2. The cells were plated, incubated, labelled and precipitable label determined as described in Example 2. Concentration dependence of IL-l/3 Oligomer (Oligo¬ mer 1) inhibition of HaCaT cells after 4 days at the indicated concentration of Oligomer is shown in Table IV along with Oligomer Cl, the mismatch Oligomer. A dose dependent inhibition of HaCaT cells by antisense IL-l/3 Oligomer (Oligomer 1) was observed, whereas no decrease in proliferation was seen with Oligomer Cl, which had a 2 nucleotide mismatch. The keratinocyte cell line showed similar inhibition to that observed with normal human keratinocytes by the antisense IL-l/3 (Oligomer 1 (1252) ) . Table IV Inhibition of HaCaT Keratinocyte Cell Line bv MP-Oligomer Against IL-l/3 MP Oligomer Cone uM 3 H-dT incorp. Inhibition of growth Control + 195,497 ± 22,445 vehicle (no Oligomer) Control 187,572 ± 8,638 (no Oligomer) Table IV (cont'd) Example 4 Inhibition of Proliferation of a Cell Line Using Antisense Oligomers to IL-lα Oligomers and HaCaT cells were treated as described in Example 3. Concentration dependence of IL-lα Oligomer [Oligo¬ mer 3 (1251-3)] treatment of HaCaT cells after 4 days at concentrations of Oligomer from 0 to 100 μM along with treatment with an antisense IL-lα Oligomer [Oligomer C3 (1588-1)] having 2 nucleotide mismatch was carried out. The role of IL-lα in inhibition of growth of the HaCaT cell line observed in this experiment was less clear than that described in Example 2 using normal keratinocytes. Addition of the antisense IL-lα Oligomer (Oligomer 3) did not result in any significant decrease in the growth of the HaCaT cells and was similar in effect to the mismatch control Oligomer C3. This find¬ ing reflects a difference between the HaCaT cell line and cultured human keratinocytes. Example 5 Inhibition of Proliferation of Keratinocytes bv Antisense Oligomers to Intracellular IL-1RA Oligomers and cells were treated as described in Examples 2 and 3. Intracellular IL-l receptor antagonist (icIL-lra) has been targeted by antisense MP Oligomers to examine its role in keratinocyte proliferation. (See, e.g.. Eisenberg, S.P., et al., Nature 343:341-346 (1990); Hannum, C.H., et al., Nature 343:336-340 (1990); Kupper, T.S., J. ' ciin. Invest. 86:1783-1789 (1990)). The intra¬ cellular IL-lra has a initiation codon region that is unique to it and not to the soluble form of IL-lra. This region provides a unique target for discriminating between the intracellular and soluble forms of the gene products. Incubation of the antisense MP Oligomer to the icIL-lra with normal human keratinocytes resulted in a strong inhibition of growth (See Table V) of >90%. The icIL-lra may have a similar function in the cell to IL-l/3 as there is strong homology between the two pro¬ teins in their amino acid sequences (March, C.J., et al., Nature (Lond.) 315:641 (1985)), and icIL-lra may not have a role as a receptor antagonist within the cell. Table V Inhibition of Normal Keratinocyte Growth With MP Oligomer Against IL-l Receptor Antagonist o er me 3 - Inhibition of growth 1 92% 97% Relative to same day control Examination of the role of icIL-lra in the keratin¬ ocyte culture was carried out using different concentra¬ tions of Oligomer 4 (1487) with HaCaT cells (See Table VI) . At the highest concentration, after 4 days of incubation, antisense Oligomer to icIL-lra (Oligomer 4) inhibited proliferation by 60%. However, decreasing concentrations of Oligomer 4 did not indicate a gradual decrease, but an abrupt change in the effectiveness of the agent occurred between 12.5 and 6.25 μM Oligomer. The inhibition of HaCaT cells at the highest concentra¬ tion of Oligomer 4 was similar to that seen with the normal keratinocyte cultures (Table V) . The mismatch Oligomer, Oligomer C4 (1607) which had 4 nucleotides switched from oiigomer 4 (1487) did not inhibit keratin- ocyte proliferation. The results of Tables V and VI suggest that the icIL-lra may also play an functional role in the regulation of keratinocyte proliferation. Table VI

Claims: Claims 1. A method of treating a pathologic condition characterized by hyperproliferation of skin or epithe¬ lial cells which comprises: exposing skin or epithelial cells to a hyper¬ proliferation inhibiting amount of an Oligomer selected from (a) an antisense Oligomer having a sequence complementary to a sequence of RNA tran¬ scribed from a target gene present in the cells; (b) a Third Strand Oligomer having a sequence com¬ plementary to a selected double stranded nucleic acid sequence of a target gene present in the cells, and (c) a Triplex Oligomer Pair which is complementary to a single stranded nucleic acid sequence of a target gene or its transcription product wherein said target gene is selected from the group consisting of those genes encoding a cytokine which mediates cellular proliferation, a modulating factor for the cytokine, a converting enzyme which converts a precursor form of the cytokine to the active cytokine, or an enzyme involved in translational or post-translational modification of said cytokine critical for its function, whereby hyperproliferation of the cells is decreased. 2. A method according to claim 1 wherein said target gene modulates cellular proliferation through an intracellular mechanism. 3. A method according to claim 2 wherein said target gene encodes IL-lα, IL-l/3 or icIL-lra, or an IL- l/3 converting enzyme. 4. A method according to claim 2 wherein said pathologic condition comprises benign hyperproliferation of keratinocytes. 5. A method according to claim 2 wherein said pathologic condition comprises malignant hyperprolifera¬ tion of keratinocytes. 6. A method according to claim 2 wherein said pathologic condition comprises benign hyperproliferation of non-epidermal epithelial cells. 7. A method according to claim 2 wherein said pathologic condition comprises malignant hyperprolifera¬ tion of non-epidermal epithelial cells. 8. A method according to claim 2 wherein said pathologic condition is psoriasis. 9. A method according to claim 2 wherein said pathologic condition comprises a chronic inflammatory disease which is perpetuated by cytokine release regu- lated by IL-lα, IL-l/3 or icIL-lra production. 10. A method according to claim 9 wherein said chronic inflammatory disease is selected from rheumatoid arthritis, inflammatory bowel disease, psoriasis, and inflammatory ocular disease. 11. A method according to claim 1 wherein said Oligomer is a neutral Oligomer. 12. A method according to claim l wherein said Oligomer is an antisense Oligomer. 13. A method according to claim 1 wherein said Oligomer is a Third Strand Oligomer or a Triplex Oligomer Pair. 14. A method of preventing or decreasing hyper¬ proliferation of skin or epithelial cells which comprises: exposing skin or epithelial cells to a hyper- proliferation-inhibiting amount of an Oligomer selected from (a) an antisense Oligomer having a sequence complementary to a sequence of RNA transcribed from a target gene present in the cells; (b) a Third Strand Oligomer having a sequence complementary to a selected double stranded nucleic acid sequence of a target gene present in the cells, and (c) a Triplex Oligomer Pair which is complementary to a single stranded nucleic acid sequence of a target gene or its transcription product wherein said target gene is selected from the group consisting of those genes encoding a cytokine which mediates cellular pro¬ liferation, a modulating factor for the cytokine, converting enzyme which converts a precursor form of the cytokine to the active cytokine, or an enzyme involved in translational or post-transla- tional modification of said cytokine critical for its function. 15. A method according to claim 14 wherein said cytokine or receptor antagonist mediates cellular proliferation through an intracellular mechanism. 16. A method according to claim 14 wherein said Oligomer is a neutral Oligomer. 17. A method according to claim 14 wherein Oligo- mer is an antisense Oligomer. 18. A method according to claim 14 wherein said Oligomer is a Third Strand Oligomer. 19. A method of preventing or decreasing hyper¬ proliferation of cells which comprises contacting said cells with a proliferation inhibiting amount of an Interleukin-1 inhibitory compound which decreases Inter- leukin-1 or intracellular Interleukin-1 receptor antago¬ nist activity. 20. A method according to claims 19 wherein said cells are epithelial cells. 21. A method according to claim 20 wherein said Interleukin-1 inhibitory compound is selected from com¬ pounds which prevent or decrease Interleukin-1 expres¬ sion or which inhibit or decrease conversion of a pre¬ cursor form of Interleukin-1 into an active form. 22. A method according to claim 21 wherein said Interleukin-1 inhibitory compound inhibits or decreases synthesis of an Interleukin-1 converting enzyme or inhi¬ bits activity of the Interleukin-1 converting enzyme. 23. A method according to claim 19 wherein the Interleukin-1 inhibitory compound is an Oligomer which prevents or decreases expression of an Interleukin-1, an Interleukin-1 modulating factor, or an Interleukin-1 converting enzyme. 24. A method according to claim 19 wherein said Interleukin-1 inhibitory compound is selected from compounds which decrease intracellular Interleukin-1 receptor antagonist activity. 25. A pharmaceutical composition which comprises a hyperproliferation inhibiting amount of an Oligomer sel¬ ected from (a) an antisense Oligomer having a sequence complementary to a sequence of RNA transcribed from a target gene present in the cells; (b) a Third Strand Oligomer having a sequence complementary to a selected double stranded nucleic acid sequence of a target gene present in the cells, and (c) a Triplex Oligomer Pair which is complementary to a single stranded nucleic acid sequence of a target gene or its transcription product wherein said target gene is selected from the group con¬ sisting of those genes encoding a cytokine which medi¬ ates cellular proliferation, a modulating factor for the cytokine, a converting enzyme which converts a precursor form of the cytokine to the active cytokine, or an enzyme involved in translational or post-translational modification of said cytokine critical for its function and a pharmaceutically acceptable carrier. 26. A composition according to claim 25 wherein the target gene encodes IL-lα, IL-l/3, icIL-lra or an IL- l / 3 converting enzyme. 27. A composition according to claim 25 wherein said Oligomer is a neutral Oligomer. 28. A composition according to claim 27 which further comprises a flux enhancer. 29. A composition according to claim 27 wherein the target gene encodes IL-lα, IL-l/3, icIL-lra or an IL- l/3 converting enzyme. 30. A composition according to claim 29 which further comprises a flux enhancer. 31. A pharmaceutical composition which comprises a hyperproliferation inhibiting amount of an Interleukin-1 inhibitory compound which decreases Interleukin-1 or intracellular Interleukin-1 receptor antagonist activity and a pharmaceutically acceptable carrier. 32. A composition according to claim 31 wherein the Interleukin-1 inhibitory compound is selected form compounds which prevent or decrease Interleukin-1 expression or which inhibit or decrease conversion of a precursor form of Interleukin-1 into an active form. 33. A composition according to claim 31 wherein said Interleukin-1 inhibitory compound inhibits or decreases synthesis of an Interleukin-1 converting enzyme or inhibits activity of the Interleukin-1 converting enzyme. 34. A composition according to claim 31 wherein the Interleukin-1 inhibitory compound is selected from compounds which decrease intracellular IL-lra activity. 35. A composition according to claim 31 wherein the Interleukin-1 inhibitory compound is an Oligomer which prevents or decreases expression of an Interleu- kin-1, an Interleukin-1 modulating factor, or an Inter¬ leukin-1 converting enzyme. 36. A composition according to claim 35 wherein said Oligomer is a neutral Oligomer. 37. A composition according to claim 36 which further comprises a flux enhancer. 38. A composition according to claim 31 wherein said Interleukin-1 inhibitory compound is an Oligomer. 39. A composition according to claim 38 wherein said Oligomer is a neutral Oligomer. 40. A composition according to claim 39 which further comprises a flux enhancer.

Inventors: COOPER KEVIN D, HAMMERBERG CRAIG, MAXWELL KAMERON W, TSENG BEN Y, COOPER, KEVIN, D., HAMMERBERG, CRAIG, MAXWELL, KAMERON, W., TSENG, BEN, Y.
Applicants: GENTA INC, UNIV MICHIGAN, GENTA INCORPORATED, UNIVERSITY OF MICHIGAN
Application year: 1993
Main classification: A61K31
IPC codes: A61K31, A61K48, A61P1, A61P27, A61P29, A61P43, C12N15